Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E Tota, Frank Struyf, Marko Merikukka, Paula Gonzalez, Aimee R Kreimer, Dan Bi, Xavier Castellsague, Newton S de Carvalho, Suzanne M Garland, Diane M Harper, Naveen Karkada, Klaus Peters, Willy AJ Pope, Carolina Porras, Wim Quint, Ana Cecilia Rodriguez, Mark Schiffman, John Schussler, S Rachel Skinner, Julio Cesar Teixeira Show all
Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2017
Awarded by NCI
The Costa Rica HPV Vaccine Trial is a long-standing collaboration between investigators in Costa Rica and the National Cancer Institute (NCI). The trial is sponsored and funded by the NCI (contract N01-CP-11005), with funding support from the National Institutes of Health Office of Research on Women's Health. GlaxoSmithKline Biologicals SA provided vaccine and support for aspects of the trial associated with regulatory submission needs of the company under a Clinical Trials Agreement (FDA BB-IND 7920) during the four-year, randomized blinded phase of our study. John T. Schiller and Douglas R. Lowy report that they are named inventors on US Government-owned HPV vaccine patents that are licensed to GlaxoSmithKline and Merck and for which the National Cancer Institute receives licensing fees. They are entitled to limited royalties as specified by federal law. The PATRICIA trial was funded by GlaxoSmithKline Biologicals SA.